Radiation therapy and vaccination against tumor-specific EGFRvIII effectively clears tumors in a murine model of head and neck squamous cell carcinoma

Lauren Uhde1,2*, Shelly Bambina1, Alejandro Alice1, Peter Lauer3, Marka Crittenden1,4,5, Keith S Bahjat1,4,6, Michael Gough1,4

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

EGFRvIII is a constitutively active and tumor-specific deletional mutant of EGFR found in multiple tumor types including glioblastoma multiforme, and has been reported in head and neck squamous cell carcinomas (HNSCC). The deletion of EGFR exons 2-7 results in a novel glycan at the junction and yields a tumor-specific antigen with demonstrated immunogenicity in mice and humans. Using a live-attenuated Listeria monocytogenes-based vaccine expressing a 21-AA neo-peptide from EGFRvIII (LmEGFRvIII), we demonstrated that prophylactic vaccination protects against subsequent challenge with an EGFRvIII-expressing squamous cell carcinoma (SCCVII-EGFRvIII). Similarly, therapeutic vaccination three days post-implantation prevented outgrowth of EGFRvIII-expressing tumors but not parental EGFRvIII-negative tumors. Conversely, we found that LmEGFRvIII vaccination was insufficient to clear large established SCCVII-EGFRvIII tumors despite eliciting large numbers of polyfunctional EGFRvIII-specific CD8+ T cells. We hypothesized that localized inflammation elicited by radiation therapy could recruit EGFRvIII-specific CD8+ T cells into the tumor. We demonstrated that while neither LmEGFRvIII vaccination nor radiation therapy alone were able to control the EGFRvIII-expressing tumors, the combination of LmEGFRvIII and radiation therapy led to tumor regression and durable cures. We are currently exploring the potential mechanisms for their synergy including the role of T cell recruitment, survival and epitope spreading.

Authors’ details
1Earle A. Chiles Research Institute, Portland, OR, USA. 2Molecular Microbiology and Immunology, OHSU, Portland, OR, USA. 3Aduro Biotech, Berkeley, CA, USA. 4Providence Cancer Center, The Oregon Clinic, Portland, OR, USA. 5The Oregon Clinic, Portland, OR, USA. 6Robert W. Franz Cancer Research Center, Portland, OR, USA.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P78

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit